Analyst cuts Boston Scientific price target to $54 amid stock underperformance and upcoming earnings.

Bernstein analyst Lee Hambright lowered the price target for Boston Scientific from $60 to $54, citing the stock's recent underperformance compared to the broader market and medical sector. Boston Scientific shares closed at $42.60 on October 2, 2026, down nearly 8% over the past month. Despite the cut, the new target still implies a potential upside of about 27%. The company is set to report earnings on October 28, with analysts expecting a slight increase in earnings per share to $0.76 and revenue growth to $5.23 billion. The consensus among 31 analysts remains moderately positive, with most rating the stock as a buy or hold.

Boston Scientific shares are trading at USD 42.87 on Pluang as of October 5, 2026, 20:33 WIB, slightly up 0.63% from the previous day. The stock's 52-week low is USD 42.60, indicating it is near its lowest point in the past year. The typical hold time for BSX on Pluang is 79 days, showing moderate investor engagement.